Cell-Signaling Inhibitor Shows In Vitro Activity.

Cites research at Ariad Pharmaceuticals on a compound that inhibits cell signaling by the Src homology 2 (SH2) protein domain in living cells, published in volume 97 of the `Proceedings of the National Academy of Science.' Design and synthesis of the AP22408 compound; Difficulties in designing SH2 inhibitors with selective in vivo activity; Potential application as a drug for osteoporosis.